CHROMIUM COMPLEXES FOR IMPROVEMENT OF MEMORY AND COGNITIVE FUNCTION

• US 20100178362A1
• Filed: 01/05/2010
• Published: 07/15/2010
• Est. Priority Date: 07/06/2007
• Status: Abandoned Application

• Current Assignee: Nutrition21 LLC
• Original Assignee: Nutrition21 LLC
• Inventors: Juturu, Vijaya, Komorowski, James R.
• Application Number:
  US12/652,282
• Publication Number:
  US 20100178362A1
• Time in Patent Office: Days
• US Class Current: 424/655
• CPC Class Codes: A23L 33/15 Vitamins
• CPC Class Codes: A23V 2002/00 Food compositions, function of food ingredients or processes for food or foodstuffs
• CPC Class Codes: A61K 31/155 Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
• CPC Class Codes: A61K 33/24 Heavy metals; Compounds thereof
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 9/00 Medicinal preparations characterised by special physical form nuclear magnetic resonance contrast preparations or magnetic resonance imaging contrast preparations A61K49/18; preparations containing radioactive substances A61K51/12
• CPC Class Codes: A61K 9/0053 Mouth and digestive tract, i.e. intraoral and peroral administration rectal administration A61K9/0031
• CPC Class Codes: A61K 9/209 containing drug in at least two layers or in the core and in at least one outer layer
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

A method of treating impaired memory and/or cognitive function by administering one or more chromium complexes, for example chromium picolinate, to an individual in need of improved memory and/or cognitive function. This method is used to improve memory and/or cognitive function associated with various disorders, including Alzheimer'"'"'s disease, dementia, and mild cognitive impairment (MCI). Chromium complexes for treating memory or cognitive impairment are also disclosed.

Claims

1. A method of treating a cognitive condition comprising:

identifying a mammal suffering from a cognitive condition; and

administering an effective amount of a chromium complex, or pharmaceutically acceptable salt thereof, to said mammal.

2. The method of claim 1, wherein the cognitive condition comprises Alzheimer'"'"'s disease.

3. The method of claim 1, wherein the cognitive condition comprises mild cognitive impairment.

4. The method of claim 1, wherein the cognitive condition comprises is associated with reduced memory functioning.

5. The method of claim 1, wherein the cognitive condition is associated with reduced brain insulin levels.

6. The method of claim 1, wherein the amount is effective to inhibit cognitive degradation.

7. The method of claim 1, wherein the amount is effective to slow progression of memory impairment.

8. The method of claim 1, wherein said chromium complex is selected from the group consisting of chromium picolinate, chromic tripicolinate, chromium nicotinate, chromic polynicotinate, chromium chloride, chromium histidinate, chromium yeast, chromium nicotinate-glycinate, chromium phenylalanine.

9. The method of claim 1, further comprising administering a cholinesterase inhibitor, memanitine, vitamin E, phospholipid or omega-3 fatty acid to said individual.

10. The method of claim 1, wherein said mammal is a human.

26. The method of claim 9, wherein said method comprises administering a cholinesterase inhibitor to said mammal, and wherein said cholinesterase inhibitor and said chromium complex are present in separate pharmaceutical formulations or nutritional supplements.

27. The method of claim 9, wherein said method comprises administering a cholinesterase inhibitor to said mammal, and wherein said cholinesterase inhibitor and said chromium complex are present in a single pharmaceutical formulation or nutritional supplement.

11. A method of treating a cognitive condition comprising:

identifying a mammal at risk of suffering from a cognitive condition; and

administering an effective amount of a chromium complex, or pharmaceutically acceptable salt thereof, to said mammal.

12. The method of claim 11, wherein the mammal has a genetic risk factor comprising a mutated gene.

13. The method of claim 11, wherein the mammal has a family history of the cognitive condition.

14. The method of claim 11, wherein the amount is effective to delay onset of the cognitive condition.

15. The method of claim 11, wherein said chromium complex is selected from the group consisting of chromium picolinate, chromic tripicolinate, chromium nicotinate, chromic polynicotinate, chromium chloride, chromium histidinate, chromium nicotinate-glycinate, chromium phenylalanine, chromium yeast.

16. The method of claim 11, further comprising administering a cholinesterase inhibitor, memanitine, vitamin E, phospholipid or omega-3 fatty acid to said individual.

28. The method of claim 16, wherein said method comprises administering a cholinesterase inhibitor to said mammal, and wherein said cholinesterase inhibitor and said chromium complex are present in separate pharmaceutical formulations or nutritional supplements.

29. The method of claim 16, wherein said method comprises administering a cholinesterase inhibitor to said mammal, and wherein said cholinesterase inhibitor and said chromium complex are present in a single pharmaceutical formulation or nutritional supplement.

17. A method of treating memory impairment comprising:

identifying a mammal suffering from age-related memory impairment; and

administering an effective amount of a chromium complex, or pharmaceutically acceptable salt thereof, to said mammal.

18. The method of claim 17, wherein the mammal is at least about 70 years old.

19. The method of claim 17, wherein the amount is effective to inhibit progression of long-term memory impairment.

20. The method of claim 17, wherein the amount is effective to inhibit progression of long-term memory impairment.

21. The method of claim 17, wherein said chromium complex is selected from the group consisting of chromium picolinate, chromic tripicolinate, chromium nicotinate, chromic polynicotinate, chromium chloride, chromium histidinate, chromium nicotinate-glycinate, chromium phenylalanine, chromium yeast.

22. The method of claim 17, further comprising administering a cholinesterase inhibitor, memanitine, vitamin E, phospholipid or omega-3 fatty acid to said individual.

30. The method of claim 22, wherein said method comprises administering a cholinesterase inhibitor to said mammal, and wherein said cholinesterase inhibitor and said chromium complex are present in separate pharmaceutical formulations or nutritional supplements.

31. The method of claim 22, wherein said method comprises administering a cholinesterase inhibitor to said mammal, and wherein said cholinesterase inhibitor and said chromium complex are present in a single pharmaceutical formulation or nutritional supplement.

23. A method for supporting cognitive function, comprising:

providing a dietary chromium complex to an individual;

advising the individual that the dietary chromium complex may support cognitive function; and

administering or self-administering the dietary chromium complex to the individual.

24. The method of claim 23, wherein the chromium complex is selected from the group consisting of chromium picolinate, chromic tripicolinate, chromium nicotinate, chromic polynicotinate, chromium chloride, chromium histidinate, chromium nicotinate-glycinate, chromium phenylalanine, chromium yeast.

25. The method of claim 23, further comprising administering a cholinesterase inhibitor, memanitine, vitamin E, phospholipid or omega-3 fatty acid to said individual.

32. The method of claim 25, wherein said method comprises administering a cholinesterase inhibitor to said mammal, and wherein said cholinesterase inhibitor and said chromium complex are present in separate pharmaceutical formulations or nutritional supplements.

33. The method of claim 25, wherein said method comprises administering a cholinesterase inhibitor to said mammal, and wherein said cholinesterase inhibitor and said chromium complex are present in a single pharmaceutical formulation or nutritional supplement.